Amneal Pharmaceuticals
Search results
Jun 1, 2024 · For more than three decades, Acadia has been at the forefront of healthcare, elevating lives by providing essential solutions to those who need them most. We pioneered the first and only approved therapies for hallucinations and delusions in Parkinson’s disease psychosis and Rett syndrome.
Our 500+ employees in San Diego, CA, Princeton, NJ and people around the world fight diseases to help brighter moments shine through for patients and their loved ones. We embrace our mission and values, so we can continue to develop innovative therapies for those who need it most.
Explore Acadia Pharmaceutical's product pipeline and see projects that are currently in development and their development phases.
May 17, 2024 · At Acadia, we remain deeply committed to providing important new therapies to patients and delivering value for our stockholders. Our Investor Center is designed to provide you with convenient access to company information.
Find the latest ACADIA Pharmaceuticals Inc. (ACAD) stock quote, history, news and other vital information to help you with your stock trading and investing.
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Sorrento Valley, San Diego, California.
4 days ago · ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment...
Get the latest ACADIA Pharmaceuticals Inc (ACAD) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
Mar 11, 2024 · SAN DIEGO--(BUSINESS WIRE)--Mar. 11, 2024-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia.
Mar 10, 2023 · Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older. — First and only approved therapy for Rett syndrome, a rare, neurodevelopmental disorder, which affects 6,000 to 9,000 patients in the U.S.1.
